141.72 USD
+0.77 (+0.55%)
Taking everything into account, NBIX scores 7 out of 10 in our fundamental rating. NBIX was compared to 530 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make NBIX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
NBIX had positive earnings in the past year.
In the past year NBIX had a positive cash flow from operations.
NBIX had positive earnings in each of the past 5 years.
NBIX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 10.03%, NBIX belongs to the top of the industry, outperforming 93.58% of the companies in the same industry.
NBIX has a better Return On Equity (14.25%) than 94.34% of its industry peers.
NBIX has a better Return On Invested Capital (11.10%) than 94.72% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NBIX is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
NBIX's Profit Margin of 15.95% is amongst the best of the industry. NBIX outperforms 92.26% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
NBIX has a Operating Margin of 20.64%. This is amongst the best in the industry. NBIX outperforms 94.91% of its industry peers.
In the last couple of years the Operating Margin of NBIX has declined.
The Gross Margin of NBIX (98.37%) is better than 97.74% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
Compared to 5 years ago, NBIX has more shares outstanding
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.26 indicates that NBIX is not in any danger for bankruptcy at the moment.
NBIX has a Altman-Z score of 8.26. This is in the better half of the industry: NBIX outperforms 79.43% of its industry peers.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.26 |
ROIC/WACC1.27
WACC8.72%
2.3 Liquidity
A Current Ratio of 3.38 indicates that NBIX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.38, NBIX is in line with its industry, outperforming 40.38% of the companies in the same industry.
A Quick Ratio of 3.27 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a Quick ratio (3.27) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.06%, which is quite good.
The Earnings Per Share has been growing by 58.39% on average over the past years. This is a very strong growth
Looking at the last year, NBIX shows a quite strong growth in Revenue. The Revenue has grown by 19.61% in the last year.
Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.05% yearly.
The Revenue is expected to grow by 12.42% on average over the next years. This is quite good.
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 33.90, NBIX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.64% of the companies listed in the same industry.
NBIX is valuated rather expensively when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 19.67, the valuation of NBIX can be described as rather expensive.
Based on the Price/Forward Earnings ratio, NBIX is valued cheaper than 94.34% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.35. NBIX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.9 | ||
| Fwd PE | 19.67 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 93.77% of the companies listed in the same industry.
NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.83 | ||
| EV/EBITDA | 20.86 |
4.3 Compensation for Growth
NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
NBIX's earnings are expected to grow with 37.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.61
PEG (5Y)0.58
EPS Next 2Y47.98%
EPS Next 3Y37.96%
5. Dividend
5.1 Amount
NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:NBIX (12/31/2025, 12:46:21 PM)
141.72
+0.77 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.43%
Inst Owner Change2.15%
Ins Owners1.01%
Ins Owner Change0.04%
Market Cap14.13B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target181.85 (28.32%)
Short Float %4.03%
Short Ratio3.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)2.53%
PT rev (3m)7.53%
EPS NQ rev (1m)0.96%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)1.62%
EPS NY rev (3m)13.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.9 | ||
| Fwd PE | 19.67 | ||
| P/S | 5.27 | ||
| P/FCF | 23.83 | ||
| P/OCF | 22.19 | ||
| P/B | 4.7 | ||
| P/tB | 4.76 | ||
| EV/EBITDA | 20.86 |
EPS(TTM)4.18
EY2.95%
EPS(NY)7.2
Fwd EY5.08%
FCF(TTM)5.95
FCFY4.2%
OCF(TTM)6.39
OCFY4.51%
SpS26.91
BVpS30.12
TBVpS29.77
PEG (NY)0.61
PEG (5Y)0.58
Graham Number53.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 8.26 |
F-Score5
WACC8.72%
ROIC/WACC1.27
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.42%
EBIT Next 3Y19.54%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What is the fundamental rating for NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to NBIX.
What is the valuation status of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
ChartMill assigns a valuation rating of 7 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.
What is the profitability of NBIX stock?
NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 8 / 10.
What are the PE and PB ratios of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 33.9 and the Price/Book (PB) ratio is 4.7.